Alphamab Oncology files HKEX next-day disclosure return on share repurchase at HKD 8.79 eachPUBT·9 hours ago09966-1.02%
Alphamab Oncology files HKEX next-day return disclosing share buyback at HKD 8.85 eachPUBT·1 day ago, 11:41 AM09966-1.02%
Alphamab Oncology files HKEX next-day disclosure return for share buyback at HKD 8.57PUBT·2 days ago, 02:27 PM09966-1.02%
Alphamab Oncology files HKEX next-day disclosure return after share repurchase at HKD 8.51PUBT·Sep 1 at 11:38 AM09966-1.02%
Alphamab Oncology files HKEX next-day disclosure return reporting share repurchase at HKD 8.9 eachPUBT·Aug 31 at 12:46 PM09966-1.02%
Alphamab Oncology launches on-market share buyback of up to HK$ 80 millionPUBT·Aug 28 at 01:55 PM09966-1.02%
Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And LossesSimplywall·Aug 28 at 12:26 PM09966-1.02%
Alphamab Oncology swings to FY26 H1 loss of RMB 40.46 million; revenue falls 15.09% to RMB 271.24 millionPUBT·Aug 27 at 02:03 PM09966-1.02%
From Private Jets to AI Hype: Surviving the Most Bizarre Corner of Hong Kong's MarketGlobal Report·Aug 25 at 11:33 AM02507+0.44%02550-1.48%
Sipai Health Hits Profitability as Tsui Wah Battles Macro HeadwindsGlobal Report·Aug 25 at 09:20 AM01709+2.11%09936-5.72%
Alphamab Oncology says China NMPA accepts Anbenitamab NDA for first-line HER2+ advanced breast cancerPUBT·Aug 18 at 10:01 AM09966-1.02%
CSPC says NMPA accepts NDA for anbenitamab, albumin-bound docetaxel neoadjuvant breast cancer combo under priority reviewPUBT·Aug 4 at 10:12 AM01093+0.78%300765-0.81%
Alphamab Oncology licenses JSKN016 ex-China rights to Pathos AI for up to USD 2.09 billionPUBT·Aug 4 at 12:00 AM09966-1.02%
Alphamab Oncology says China CDE clears JSKN033 Phase 3 trial in recurrent or metastatic cervical cancerPUBT·Aug 3 at 01:45 PM09966-1.02%
The HK Market's Island of Misfit Toys: Who is Pivoting and Who is Sleepwalking?Global Report·Jul 29 at 09:18 AM02197+3.96%02408+2.65%
